Stockscreener 앱 받기
62.00
0.44%
0.27
시간 외 거래:
62.00
전일 마감가:
$61.73
열려 있는:
$57.79
하루 거래량:
424.78K
Relative Volume:
0.64
시가총액:
$1.32B
수익:
$56.54M
순이익/손실:
$-30.70M
주가수익비율:
-158.97
EPS:
-0.39
순현금흐름:
$-31.05M
1주 성능:
-1.43%
1개월 성능:
+22.89%
6개월 성능:
+185.98%
1년 성능:
+434.94%
1일 변동 폭
$56.53
$62.38
1주일 범위
$56.53
$63.48
52주 변동 폭
$10.14
$66.94
Cidara Therapeutics Inc Stock (CDTX) Company Profile
명칭
Cidara Therapeutics Inc
전화
858-752-6170
주소
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
CDTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
62.00 | 1.37B | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-03-12 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-27 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-08 | 개시 | Guggenheim | Buy |
| 2024-08-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | 재개 | H.C. Wainwright | Buy |
| 2021-09-22 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | 개시 | Aegis Capital | Buy |
| 2019-09-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-07-26 | 개시 | Citigroup | Buy |
| 2017-04-21 | 개시 | Raymond James | Strong Buy |
| 2017-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Ladenburg Thalmann | Buy |
| 2017-04-11 | 재개 | Wedbush | Outperform |
| 2017-02-22 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-22 | 업그레이드 | WBB Securities | Sell → Hold |
| 2016-12-21 | 재개 | Leerink Partners | Outperform |
| 2016-12-19 | 개시 | H.C. Wainwright | Buy |
| 2016-09-23 | 다운그레이드 | WBB Securities | Hold → Sell |
| 2015-10-09 | 업그레이드 | WBB Securities | Sell → Hold |
| 2015-05-11 | 개시 | Jefferies | Buy |
| 2015-05-11 | 개시 | Leerink Partners | Outperform |
| 2015-05-11 | 개시 | Needham | Buy |
| 2015-05-11 | 개시 | Wedbush | Outperform |
| 2015-04-23 | 개시 | WBB Securities | Sell |
모두보기
Cidara Therapeutics Inc 주식(CDTX)의 최신 뉴스
A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛
Cidara (CDTX) Q2 Cash Surges 163% - AOL.com
Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks
Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada
Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize
Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com
Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate
Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Cidara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Cidara Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82) - TipRanks
Cidara Therapeutics Q2 net loss narrows - MarketScreener
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks
RBC Capital raises Cidara Therapeutics stock price target to $115 on market potential - Investing.com Canada
Cidara Therapeutics price target raised to $115 from $75 at RBC Capital - TipRanks
Cidara Therapeutics Inc expected to post a loss of $2.00 a shareEarnings Preview - TradingView
Cidara Therapeutics CDTX Q2 2025 Earnings Preview Upside Potential on Analyst Optimism - AInvest
Is Cidara Therapeutics Inc. stock overvalued or undervaluedCapitalize on market momentum for maximum gains - Jammu Links News
Should I hold or sell Cidara Therapeutics Inc. stock in 2025Achieve breakthrough gains with expert advice - Jammu Links News
Cidara Therapeutics Inc. Stock Analysis and ForecastInvest smarter with data-backed insights - Jammu Links News
How strong is Cidara Therapeutics Inc. company’s balance sheetGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Cidara Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
What makes Cidara Therapeutics Inc. stock price move sharplyRecord-breaking capital gains - Jammu Links News
Is Cidara Therapeutics Inc. a good long term investmentInvest with confidence backed by data - Jammu Links News
What are analysts’ price targets for Cidara Therapeutics Inc. in the next 12 monthsDynamic portfolio growth - Jammu Links News
What is the risk reward ratio of investing in Cidara Therapeutics Inc. stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
What is the dividend policy of Cidara Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What are Cidara Therapeutics Inc. company’s key revenue driversAchieve rapid capital gains with smart investing - Jammu Links News
Will Cidara Therapeutics Inc. Bounce From 52 Week LowTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Moving Average Crossover Confirms Uptrend in Cidara Therapeutics Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How Cidara Therapeutics Inc. stock performs during market volatilityHigh Win Rate Trading Opportunities Detected - beatles.ru
Can trapped investors hope for a rebound in Cidara Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Will Cidara Therapeutics Inc. stock split in the near futureInvestment Strategy With Predictable Gains Outlined - metal.it
Candidemia Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Cidara Therapeutics, Scynexis, Merck, Basilea Pharmaceutica, Lupin Pharmaceuticals, Astellas PharmaResearchAndMarkets.com - FinancialContent
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionBuy Signal Based on Chart Analysis Confirmed - metal.it
Why is Cidara Therapeutics Inc. stock attracting strong analyst attentionFree Market Volatility Navigation Tips - Jammu Links News
What is Cidara Therapeutics Inc. company’s growth strategySwing Trade Updates To Watch Now - jammulinksnews.com
Why Cidara Therapeutics Inc. stock attracts strong analyst attention Fundamental + Technical Combined Watchlist - metal.it
Published on: 2025-07-28 06:14:55 - Jammu Links News
How does Cidara Therapeutics Inc. compare to its industry peersDiscover breakthrough trading strategies - jammulinksnews.com
Cidara Therapeutics Inc (CDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):